Wang Dan-Dan, Jin Yan, Wang Chao, Kim Yeon-Ju, Perez Zuly Elizabeth Jimenez, Baek Nam In, Mathiyalagan Ramya, Markus Josua, Yang Deok-Chun
Department of Oriental Medicinal Biotechnology, Ginseng Bank, College of Life Science, Kyung Hee University, Replubic of Korea.
Graduate School of Biotechnology, College of Life Science, Kyung Hee University, Replubic of Korea.
J Ginseng Res. 2018 Jan;42(1):42-49. doi: 10.1016/j.jgr.2016.12.009. Epub 2016 Dec 24.
Ginsenoside F1 has been described to possess skin-whitening effects on humans. We aimed to synthesize a new ginsenoside derivative from F1 and investigate its cytotoxicity and melanogenesis inhibitory activity in B16BL6 cells using recombinant glycosyltransferase enzyme. Glycosylation has the advantage of synthesizing rare chemical compounds from common compounds with great ease.
UDP-glycosyltransferase (BSGT1) gene from was selected for cloning. The recombinant glycosyltransferase enzyme was purified, characterized, and utilized to enzymatically transform F1 into its derivative. The new product was characterized by NMR techniques and evaluated by MTT, melanin count, and tyrosinase inhibition assay.
The new derivative was identified as (20)-3,6,12,20-tetrahydroxydammar-24-ene-20---D-glucopyranosyl-3---D-glucopyranoside (ginsenoside Ia), which possesses an additional glucose linked into the C-3 position of substrate F1. Ia had been previously reported; however, no biological activity was further examined. This study focused on the mass production of arduous ginsenoside Ia from accessible F1 and its inhibitory effect of melanogenesis in B16BL6 cells. Ia showed greater inhibition of melanin and tyrosinase at 100 μmol/L than F1 and arbutin. These results suggested that Ia decreased cellular melanin synthesis in B16BL6 cells through downregulation of tyrosinase activity.
To our knowledge, this is the first study to report on the mass production of rare ginsenoside Ia from F1 using recombinant UDP-glycosyltransferase isolated from and its superior melanogenesis inhibitory activity in B16BL6 cells as compared to its precursor. In brief, ginsenoside Ia can be applied for further study in cosmetics.
人参皂苷F1已被描述对人类具有美白作用。我们旨在从F1合成一种新的人参皂苷衍生物,并使用重组糖基转移酶研究其在B16BL6细胞中的细胞毒性和黑色素生成抑制活性。糖基化具有从常见化合物轻松合成稀有化合物的优势。
选择来自的UDP-糖基转移酶(BSGT1)基因进行克隆。对重组糖基转移酶进行纯化、表征,并用于将F1酶促转化为其衍生物。通过核磁共振技术对新产品进行表征,并通过MTT、黑色素计数和酪氨酸酶抑制试验进行评估。
新衍生物被鉴定为(20)-3,6,12,20-四羟基达玛-24-烯-20---D-吡喃葡萄糖基-3---D-吡喃葡萄糖苷(人参皂苷Ia),它在底物F1的C-3位连接了一个额外的葡萄糖。Ia此前已有报道;然而,未进一步研究其生物活性。本研究重点在于从易得的F1大量生产难以获得的人参皂苷Ia及其对B16BL6细胞黑色素生成的抑制作用。在100μmol/L时,Ia对黑色素和酪氨酸酶的抑制作用比F1和熊果苷更强。这些结果表明,Ia通过下调酪氨酸酶活性降低了B16BL6细胞中的细胞黑色素合成。
据我们所知,这是第一项报道使用从分离的重组UDP-糖基转移酶从F1大量生产稀有人参皂苷Ia及其在B16BL6细胞中比其前体具有更强的黑色素生成抑制活性的研究。简而言之,人参皂苷Ia可用于化妆品的进一步研究。